http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#Head http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#assertion http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#provenance http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#pubinfo http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#assertion http://purl.obolibrary.org/obo/DOID_3908 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3908 http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00530 http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association http://www.w3.org/2000/01/rdf-schema#label erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5 http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00530 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#provenance http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#pubinfo http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig http://purl.org/nanopub/x/hasSignature ANZ9f2Iibw4BE+OPoztuDipJkIp+6xTk+HHCC146oC8/FeUAw2CZWhGLFiULasM2ExJjh+F8Dnkuf8h75TPMyJSWEdRxMdTXlIzeLtcM6XmgcC5XOVyFpHYQ9Ka7Z3MVXTSDVnNv5fwjUFZm1JBg0vXXhz1Bl7Mnt0sigYWkiCY= http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://purl.org/dc/terms/created 2021-06-15T18:17:22.636+02:00 http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA9tplnxsJpXgLNa8bDwtx0t5Hv-IxqQFlcWTXnrQUCRU https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs